Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | EIF4E | P06730 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TOP1 | P11387 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | THPO | P40225 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | ATG7 | O95352 | 2/20 | 0.34 |
| ▸ | PNP | P00491 | 3/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12151511 | 0.82 | LMNA (0.34) | LMNASMN1; SMN2ADORA1ALDH1A1GLA | |
| SCHEMBL16199367 | 0.79 | LMNA (0.60) | LMNASMN1; SMN2ADORA1ALDH1A1GLA | |
| SCHEMBL13320587 | 0.74 | LMNA (0.59) | LMNASMN1; SMN2ADORA1ALDH1A1GLA | |
| SCHEMBL13352081 | 0.74 | LMNA (0.59) | LMNASMN1; SMN2ADORA1ALDH1A1GLA | |
| SCHEMBL12151512 | 0.73 | ADORA3 (0.44) | LMNASMN1; SMN2ADORA1ALDH1A1GLA | |
| SCHEMBL12150458 | 0.73 | LMNA (0.45) | LMNASMN1; SMN2ADORA1ALDH1A1GLA | |
| SCHEMBL9780402 | 0.72 | ATG7 (0.58) | ATG7 | |
| SCHEMBL6917119 | 0.71 | LMNA (0.42) | LMNASMN1; SMN2ADORA1ALDH1A1GLA | |
| SCHEMBL12300351 | 0.71 | LMNA (0.44) | LMNASMN1; SMN2ADORA1ALDH1A1GLA | |
| SCHEMBL6914219 | 0.68 | LMNA (0.40) | LMNASMN1; SMN2ADORA1ALDH1A1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9139604-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20150025039-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. | 2015-01-22 | — | — | US | disclosed |
| US-8022083-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2011-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025039-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | TYMP, ITPA, PNP | LMNA 2918/4885SMN1; SMN2 2517/4885ADORA1 1306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.